The Latest Cardiac and Vascular News
PARIS, March 14, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat resistant/hard-to-treat hypertension and heart failure, announces that Stéphane Cohen, a pharmacist and ESSEC graduate, is joining the team as Director […]
Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full study population Firibastat demonstrated better efficacy compared to ramipril in severe patients with low ejection fraction Firibastat improved blood pressure profile in […]
PARIS, July 08, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the enrollment of the first patient in the Company’s REFRESH study […]
PARIS, July 05, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant high blood pressure and heart failure, will present results of a preclinical study of QGC606 in heart failure […]
PARIS, May 19, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension and heart failure, announces the publication in Biomedicine & Pharmacotherapy of a new peer-reviewed scientific article […]
€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs PARIS, April 28, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the […]
PARIS, April 21, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart […]
PARIS and NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, announces the end of its collaboration with Chinese Pharma […]
Recruitment of first subjects for Phase III trial in difficult-to-treat and resistant arterial hypertension patients Finalization of recruitment for Phase IIb trial in heart failure with upcoming results expected in 2021 Strong cash position of €27.1 million at December 2020 Licensing agreement activities acceleration in second semester 2020 PARIS and […]
PARIS and NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs that directly targets the brain to treat difficult-to-treat/resistant hypertension and heart failure, today announced that Orient EuroPharma Co. Ltd (OEP) […]
